Post by Octant

We’re excited to announce a collaboration with the Foundation Fighting Blindness to conduct a natural history study of people with inherited retinal diseases caused by mutations in the RHO gene. This study expands the Foundation’s Uni-Rare natural history study with a new four-year cohort, intended to deepen understanding of disease progression and help inform future clinical trial design in rhodopsin-associated retinal disease. The collaboration complements our broader efforts in RHO-adRP, including the clinical development of OCT-980, our investigational oral small molecule being studied in an ongoing Phase 1/2 trial. High-quality natural history data enable better studies in genetically defined retinal diseases, and we’re proud to work alongside the Foundation Fighting Blindness on this important effort. Read the full press release here: https://lnkd.in/g7yC9p3p